Trade Inari Medical, Inc. - NARI CFD
Market information is presented
as of 2023-09-21
- Summary
| Spread | - | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Inari Medical Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | N/A |
| Open* | N/A |
| 1-Year Change* | N/A |
| Day's Range* | N/A |
| 52 wk Range | 52.59-83.84 |
| Average Volume (10 days) | 475.88K |
| Average Volume (3 months) | 16.03M |
| Market Cap | 3.62B |
| P/E Ratio | -100.00K |
| Shares Outstanding | 57.35M |
| Revenue | 439.15M |
| EPS | -0.30 |
| Dividend (Yield %) | N/A |
| Beta | 1.01 |
| Next Earnings Date | Oct 31, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
Inari Medical, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Tuesday, October 31, 2023 | ||
| Time (UTC) 10:59 | Country US
| Event Q3 2023 Inari Medical Inc Earnings Release Q3 2023 Inari Medical Inc Earnings ReleaseForecast -Previous - |
| Monday, February 26, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q4 2023 Inari Medical Inc Earnings Release Q4 2023 Inari Medical Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 383.471 | 276.984 | 139.67 | 51.1289 | 6.82877 |
| Revenue | 383.471 | 276.984 | 139.67 | 51.1289 | 6.82877 |
| Cost of Revenue, Total | 44.506 | 24.757 | 12.971 | 5.81874 | 1.28049 |
| Gross Profit | 338.965 | 252.227 | 126.699 | 45.3102 | 5.54828 |
| Total Operating Expense | 411.57 | 266.14 | 121.899 | 50.5326 | 15.9682 |
| Selling/General/Admin. Expenses, Total | 288.545 | 187.776 | 88.505 | 37.1533 | 10.6979 |
| Research & Development | 74.221 | 51.018 | 18.399 | 7.2199 | 3.98975 |
| Operating Income | -28.099 | 10.844 | 17.771 | 0.59633 | -9.13938 |
| Interest Income (Expense), Net Non-Operating | 1.558 | -0.141 | -0.651 | -0.83135 | -0.79509 |
| Other, Net | 0.356 | -0.018 | -3.331 | -0.95681 | -0.21821 |
| Net Income Before Taxes | -26.185 | 10.685 | 13.789 | -1.19183 | -10.1527 |
| Net Income After Taxes | -29.267 | 9.84 | 13.789 | -1.19183 | -10.1527 |
| Net Income Before Extra. Items | -29.267 | 9.84 | 13.789 | -1.19183 | -10.1527 |
| Net Income | -29.267 | 9.84 | 13.789 | -1.19183 | -10.1527 |
| Income Available to Common Excl. Extra. Items | -29.267 | 9.84 | 13.789 | -1.19183 | -10.1527 |
| Income Available to Common Incl. Extra. Items | -29.267 | 9.84 | 13.789 | -1.19183 | -10.1527 |
| Diluted Net Income | -29.267 | 9.84 | 13.789 | -1.19183 | -10.1527 |
| Diluted Weighted Average Shares | 52.8377 | 55.5942 | 49.2516 | 46.0808 | 46.0808 |
| Diluted EPS Excluding Extraordinary Items | -0.5539 | 0.177 | 0.27997 | -0.02586 | -0.22032 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Diluted Normalized EPS | -0.5539 | 0.177 | 0.29794 | -0.01882 | -0.21968 |
| Depreciation / Amortization | 4.298 | 2.589 | 1.139 | 0.016 | |
| Unusual Expense (Income) | 0.885 | 0.32462 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 119.005 | 116.167 | 107.771 | 96.204 | 92.744 |
| Revenue | 119.005 | 116.167 | 107.771 | 96.204 | 92.744 |
| Cost of Revenue, Total | 13.844 | 13.741 | 13.128 | 11.064 | 10.347 |
| Gross Profit | 105.161 | 102.426 | 94.643 | 85.14 | 82.397 |
| Total Operating Expense | 120.515 | 121.505 | 113.662 | 106.002 | 102.072 |
| Selling/General/Admin. Expenses, Total | 84.454 | 84.606 | 79.116 | 74.886 | 72.186 |
| Research & Development | 21.085 | 22.064 | 20.412 | 19.105 | 18.569 |
| Depreciation / Amortization | 1.132 | 1.094 | 1.006 | 0.947 | 0.97 |
| Operating Income | -1.51 | -5.338 | -5.891 | -9.798 | -9.328 |
| Interest Income (Expense), Net Non-Operating | 4.508 | 4.105 | 0.896 | 0.544 | 0.141 |
| Other, Net | 0.026 | 0.039 | 0.187 | -0.059 | 0.252 |
| Net Income Before Taxes | 3.024 | -1.194 | -4.808 | -9.313 | -8.935 |
| Net Income After Taxes | 2.085 | -2.218 | -5.798 | -10.153 | -10.187 |
| Net Income Before Extra. Items | 2.085 | -2.218 | -5.798 | -10.153 | -10.187 |
| Net Income | 2.085 | -2.218 | -5.798 | -10.153 | -10.187 |
| Income Available to Common Excl. Extra. Items | 2.085 | -2.218 | -5.798 | -10.153 | -10.187 |
| Income Available to Common Incl. Extra. Items | 2.085 | -2.218 | -5.798 | -10.153 | -10.187 |
| Diluted Net Income | 2.085 | -2.218 | -5.798 | -10.153 | -10.187 |
| Diluted Weighted Average Shares | 58.4963 | 54.756 | 53.6927 | 53.4916 | 53.1838 |
| Diluted EPS Excluding Extraordinary Items | 0.03564 | -0.04051 | -0.10798 | -0.18981 | -0.19154 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | 0.03564 | -0.04051 | -0.10798 | -0.18981 | -0.19154 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 422.905 | 245.198 | 205.673 | 39.4084 | 25.9644 |
| Cash and Short Term Investments | 326.401 | 176.1 | 164.21 | 23.6393 | 21.8337 |
| Cash & Equivalents | 60.222 | 92.752 | 114.229 | 23.6393 | 21.8337 |
| Total Receivables, Net | 58.611 | 42.351 | 28.008 | 11.3018 | 2.2295 |
| Accounts Receivable - Trade, Net | 58.611 | 42.351 | 28.008 | 11.3018 | 2.2295 |
| Total Inventory | 32.581 | 21.053 | 10.597 | 3.95321 | 1.09334 |
| Prepaid Expenses | 5.312 | 5.694 | 2.808 | 0.46408 | 0.75786 |
| Other Current Assets, Total | 0.05 | 0.05 | 0.05 | ||
| Total Assets | 504.152 | 311.542 | 214.092 | 44.5466 | 26.9015 |
| Property/Plant/Equipment, Total - Net | 72.358 | 61.38 | 7.498 | 3.33112 | 0.91996 |
| Property/Plant/Equipment, Total - Gross | 81.186 | 66.161 | 9.531 | 4.61026 | 1.98083 |
| Accumulated Depreciation, Total | -8.828 | -4.781 | -2.033 | -1.27914 | -1.06087 |
| Other Long Term Assets, Total | 0.589 | 0.981 | 0.921 | 1.80706 | 0.01708 |
| Total Current Liabilities | 56.174 | 42.513 | 13.838 | 8.8702 | 2.12785 |
| Accounts Payable | 7.659 | 6.541 | 3.047 | 2.5488 | 0.71409 |
| Accrued Expenses | 48.515 | 35.972 | 10.791 | 6.32139 | 1.41376 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 87.15 | 72.333 | 13.838 | 29.5202 | 12.1768 |
| Total Long Term Debt | 0 | 0 | 0 | 19.4807 | 9.83641 |
| Long Term Debt | 0 | 19.4807 | 9.83641 | ||
| Other Liabilities, Total | 30.976 | 29.82 | 0 | 1.16934 | 0.21253 |
| Total Equity | 417.002 | 239.209 | 200.254 | 15.0264 | 14.7247 |
| Redeemable Preferred Stock | 0 | 54.1702 | 54.1702 | ||
| Common Stock | 0.054 | 0.05 | 0.049 | 0.0096 | 0.00901 |
| Additional Paid-In Capital | 462.949 | 257.144 | 227.624 | 2.05837 | 1.42695 |
| Retained Earnings (Accumulated Deficit) | -46.85 | -17.583 | -27.423 | -41.2118 | -40.1235 |
| Other Equity, Total | 0.849 | -0.379 | 0.004 | 0 | -0.75798 |
| Total Liabilities & Shareholders’ Equity | 504.152 | 311.542 | 214.092 | 44.5466 | 26.9015 |
| Total Common Shares Outstanding | 54.0217 | 50.3134 | 49.2516 | 46.0808 | 46.0808 |
| Short Term Investments | 266.179 | 83.348 | 49.981 | ||
| Long Term Investments | 8.3 | 3.983 | |||
| Unrealized Gain (Loss) | -0.023 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 425.606 | 422.905 | 410.571 | 411.338 | 413.339 |
| Cash and Short Term Investments | 328.446 | 326.401 | 319.233 | 330.496 | 338.712 |
| Cash & Equivalents | 56.562 | 60.222 | 83.528 | 79.724 | 186.556 |
| Short Term Investments | 271.884 | 266.179 | 235.705 | 250.772 | 152.156 |
| Total Receivables, Net | 55.719 | 58.611 | 54.059 | 49.171 | 44.95 |
| Accounts Receivable - Trade, Net | 55.719 | 58.611 | 54.059 | 49.171 | 44.95 |
| Total Inventory | 36.499 | 32.581 | 29.67 | 26.674 | 23.828 |
| Prepaid Expenses | 4.942 | 5.312 | 7.609 | 4.997 | 5.849 |
| Other Current Assets, Total | |||||
| Total Assets | 506.534 | 504.152 | 487.819 | 484.262 | 484.109 |
| Property/Plant/Equipment, Total - Net | 71.844 | 72.358 | 71.142 | 66.729 | 64.554 |
| Property/Plant/Equipment, Total - Gross | 81.997 | 81.186 | 79.165 | 73.641 | 70.354 |
| Accumulated Depreciation, Total | -10.153 | -8.828 | -8.023 | -6.912 | -5.8 |
| Other Long Term Assets, Total | 9.084 | 8.889 | 6.106 | 6.195 | 6.216 |
| Total Current Liabilities | 48.34 | 56.174 | 42.343 | 40.984 | 35.58 |
| Accounts Payable | 7.352 | 7.659 | 6.035 | 4.748 | 6.066 |
| Accrued Expenses | 40.988 | 48.515 | 36.308 | 36.236 | 29.514 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 79.798 | 87.15 | 72.72 | 70.484 | 65.297 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 31.458 | 30.976 | 30.377 | 29.5 | 29.717 |
| Total Equity | 426.736 | 417.002 | 415.099 | 413.778 | 418.812 |
| Common Stock | 0.057 | 0.054 | 0.053 | 0.053 | 0.053 |
| Additional Paid-In Capital | 475.754 | 462.949 | 457.043 | 445.807 | 440.238 |
| Retained Earnings (Accumulated Deficit) | -49.068 | -46.85 | -41.052 | -30.899 | -20.712 |
| Other Equity, Total | -0.007 | 0.849 | -0.945 | -1.183 | -0.767 |
| Total Liabilities & Shareholders’ Equity | 506.534 | 504.152 | 487.819 | 484.262 | 484.109 |
| Total Common Shares Outstanding | 57.0837 | 54.0217 | 53.5953 | 53.3058 | 53.0229 |
| Long Term Investments | 0 | 0 | 0 | 0 | |
| Redeemable Preferred Stock | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -29.267 | 9.84 | 13.789 | -1.19183 | -10.1527 |
| Cash From Operating Activities | -13.972 | 25.486 | 1.912 | -4.9359 | -10.8921 |
| Cash From Operating Activities | 4.673 | 3.034 | 1.385 | 0.61352 | 0.28305 |
| Non-Cash Items | 32.09 | 26.912 | 7.907 | 1.9017 | 0.49788 |
| Cash Taxes Paid | 3.417 | 0.472 | 0.154 | 0.01381 | 0.01567 |
| Cash Interest Paid | 0.151 | 0.151 | 0.999 | 0.80993 | 0.74722 |
| Changes in Working Capital | -21.468 | -14.3 | -21.169 | -6.2593 | -1.52036 |
| Cash From Investing Activities | -195.216 | -51.022 | -55.437 | -3.14414 | -0.7527 |
| Capital Expenditures | -9.951 | -13.645 | -5.46 | -3.14414 | -0.7527 |
| Cash From Financing Activities | 177.138 | 4.073 | 144.115 | 10.2235 | 26.7577 |
| Financing Cash Flow Items | -6.489 | -2.354 | -0.467 | 0.23632 | -0.25616 |
| Issuance (Retirement) of Stock, Net | 183.627 | 6.427 | 164.832 | 0.12721 | 27.0139 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | -20.25 | 9.86 | 0 |
| Net Change in Cash | -32.53 | -21.865 | 90.59 | 2.14349 | 15.1129 |
| Other Investing Cash Flow Items, Total | -185.265 | -37.377 | -49.977 | ||
| Foreign Exchange Effects | -0.48 | -0.402 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -2.218 | -29.267 | -23.469 | -13.316 | -3.129 |
| Cash From Operating Activities | -2.013 | -13.972 | -25.227 | -12.161 | -9.1 |
| Cash From Operating Activities | 1.348 | 4.673 | 3.43 | 2.26 | 1.063 |
| Non-Cash Items | 8.279 | 32.09 | 23.346 | 15.082 | 7.274 |
| Cash Taxes Paid | 0.104 | 3.417 | 3.085 | 2.297 | 0.089 |
| Cash Interest Paid | 0.032 | 0.151 | 0.112 | 0.075 | 0.037 |
| Changes in Working Capital | -9.422 | -21.468 | -28.534 | -16.187 | -14.308 |
| Cash From Investing Activities | -4.043 | -195.216 | -161.969 | -175.371 | -73.511 |
| Capital Expenditures | -0.964 | -9.951 | -8.173 | -5.864 | -2.745 |
| Other Investing Cash Flow Items, Total | -3.079 | -185.265 | -153.796 | -169.507 | -70.766 |
| Cash From Financing Activities | 2.466 | 177.138 | 178.827 | 174.947 | 176.542 |
| Financing Cash Flow Items | -1.932 | -6.489 | -4.599 | -3.375 | -1.624 |
| Issuance (Retirement) of Stock, Net | 4.398 | 183.627 | 183.426 | 178.322 | 178.166 |
| Issuance (Retirement) of Debt, Net | 0 | ||||
| Foreign Exchange Effects | -0.07 | -0.48 | -0.855 | -0.443 | -0.127 |
| Net Change in Cash | -3.66 | -32.53 | -9.224 | -13.028 | 93.804 |
Inari Medical, Inc. Company profile
About Inari Medical Inc
Inari Medical, Inc. is a medical device company. The Company operates through the development and commercialization of invasive mechanical thrombectomy devices to treat thromboembolism in the venous system. Its product offerings consist of two minimally invasive, catheter-based mechanical thrombectomy systems, which are for venous system and the treatment of the two distinct manifestations of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE). The Company’s products include ClotTriever System, FlowTriever System, FlowSaver, FlowStasis and FlowTriever 2. The ClotTriever system is a mechanical thrombectomy system designed to core, capture and remove large clots from large vessels and is used to treat DVT and its components include ClotTriever Catheter and ClotTriever Sheath. The FlowTriever is a large bore catheter-based aspiration and mechanical thrombectomy system designed to remove large clots from large vessels to treat PE.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Inari Medical Inc revenues increased 98% to $277M. Net income decreased 29% to $9.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Selling, general and administrative - Ba increase of 93% to $165.1M (expense), Research and development - Balancing val increase from $17.8M to $48.8M (expense).
| Industry: | Medical Equipment |
6001 Oak Canyon, Suite 100
IRVINE
CALIFORNIA 92618
US
News
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com